Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

5.0%

1 terminated/withdrawn out of 20 trials

Success Rate

95.0%

+8.5% vs industry average

Late-Stage Pipeline

25%

5 trials in Phase 3/4

Results Transparency

32%

6 of 19 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 1
11(55.0%)
Phase 3
5(25.0%)
Phase 2
4(20.0%)
20Total
Phase 1(11)
Phase 3(5)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT01363063Phase 1Completed

Study of the Tolerability of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers

Role: lead

NCT01365650Phase 1Completed

Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis

Role: lead

NCT02716857Phase 3Completed

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

Role: lead

NCT02603705Phase 3Completed

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Role: lead

NCT02102516Phase 3Completed

SPRIX in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures

Role: lead

NCT01355588Phase 1Completed

Tolerability, Safety and Pharmacokinetics of Four Formulations of Ketorolac Tromethamine in Healthy Volunteers

Role: lead

NCT01363050Phase 1Completed

Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers

Role: lead

NCT01363076Phase 1Completed

The Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years

Role: lead

NCT01365611Phase 1Completed

Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects

Role: lead

NCT01356225Phase 2Completed

A Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery

Role: lead

NCT01363089Phase 1Completed

Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine

Role: lead

NCT01347853Phase 3Completed

Safety and Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain

Role: lead

NCT00266786Phase 3Completed

Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery

Role: lead

NCT01356212Phase 1Completed

Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device

Role: lead

NCT00483717Phase 2Completed

Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine

Role: lead

NCT00802308Phase 1Completed

Effects of a Single Dose of Egalet® Morphine Combined With a Single Dose of Alcohol in Healthy Moderate Drinkers

Role: lead

NCT00446069Phase 2Completed

A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients

Role: lead

NCT00802087Phase 1Completed

Single Dose Pharmacokinetics of Egalet® Hydrocodone

Role: lead

NCT00444834Phase 2Terminated

A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension

Role: lead

NCT00801788Phase 1Completed

Single Dose Pharmacokinetics of Egalet® Oxycodone

Role: lead

All 20 trials loaded